Dr Andrew Weng
Bernard and Francine Dorval Prize recipient in 2013
Dr Andrew Weng is a physician-scientist who has made tremendous contributions in the area of basic biomedical science to advance scientific understanding of the processes driving the onset of leukemia. In particular, his work has significant implications for the treatment of T-cell acute leukemia and is likely to have implications for other blood cancers.
As a postdoctoral fellow at Harvard Medical School, Dr Weng distinguished himself as first author on groundbreaking papers on Notch signalling in leukemia. One of these, in Science, has been cited almost 1,000 times and transformed the research community’s view of Notch’s role in leukemias and lymphomas – from peripheral involvement to a central player. Two other papers, on the Myc gene’s importance in T-cell transformation and on a method to rapidly identify Notch transcriptional targets, have both been cited more than 200 times.
Since establishing his lab at the BC Cancer Agency in 2004 he has continued to build our knowledge of Notch through a series of findings published in high impact journals including Blood, The Journal of Experimental Medicine, and Nature Medicine. This last paper identified a biomarker for leukemia-initiating cells in both a mouse model and human samples, and identified a regulator of this marker, suggesting further therapeutic targets.
Dr Weng is the Director of the Clinical Flow cytometry laboratory at the BC Cancer Agency and an associate professor, pathology and laboratory medicine at the University of British Columbia.
His authority on the topic of Notch is internationally recognized and he has been an invited speaker at many prestigious scientific meetings. He has demonstrated integrity, collaborative spirit and leadership in his career. He is recognized by his peers as a rigorous scientist, an extremely strong mentor and an excellent clinician. His work shows great promise and he is poised to be a leader in the field.
We realize that our efforts cannot even be compared to what women face when they hear the words ... ‘you have cancer.’
Together we can reduce the burden of cancer
Last year, we only had the resources available to fund 40% of high-priority research projects. Imagine the impact we could have if we were able to fund 100%.